Glivec case: More time sought on appellate board composition
Popularity Report
 |
|||
|
|||
|
|||
|
|||
|
|||
|
Rank
Bookmark History
Public Sticky notes
The Centre has asked the Supreme Court for more time to come up with its suggestion on the composition of the Intellectual Property Appellate Board (IPAB), with regard to having a technical member on the Board.
The IPAB composition is significant, as it will look into the rejection of Novartis’ patent application on its cancer drug Glivec. But the IPAB profile had caused Novartis some heart-burn in the past, as the technical member on the IPAB was the former patent controller, Mr S. Chandrasekaran, under whom Novartis’ patent application on Glivec had been rejected in the first place, in 2006.
Highlighted by gibreel
Public Comment